Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
1
33%
Ph early_phase_1
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (33.3%)
Phase 11 (33.3%)
Phase 21 (33.3%)

Trials by Status

recruiting267%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
completedearly_phase_1

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02111941
recruitingphase_2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

NCT06639074
recruitingphase_1

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT05920798

Clinical Trials (3)

Showing 3 of 3 trials
NCT02111941Early Phase 1

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed
NCT06639074Phase 2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Recruiting
NCT05920798Phase 1

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3